Target intelligence / Profile preview

TRAF-interacting protein with FHA domain-containing protein B (TIFAB)

Target
TIFAB
Molecular classification
Other (adapter/regulatory protein[1][3]), Not a receptor, enzyme, ion channel, or transporter
01

Overview

TIFAB is a protein homologous to TIFA, but with truncated N- and C- terminal regions. It binds directly to TIFA and inhibits TIFA-mediated activation of NF-κB—a key pathway in innate immunity and inflammation—by blocking the formation of TIFA-TRAF6 signaling complexes[1][3]. While TIFA itself is a hub for immune activation and DNA damage response, TIFAB serves as a negative regulator, modulating the extent and duration of these signals. Thus, TIFAB is best thought of as a protein modulator within immune signaling networks rather than as a classical receptor, drug target, or enzyme[1][3].

Other names
TIFABTIFA-like proteinTIFA-related protein TIFABTRAF-interacting protein with forkhead-associated domain family member B
02

Mechanism of action

Inhibits TIFA-triggered TRAF6 signaling and downstream NF-κB activation by binding to TIFA and blocking its oligomerization or activity[1][3].

03

Biological functions

Negative regulation of TIFA-mediated NF-κB signaling[1][3]Modulation of innate immunity and inflammatory response[1]
04

Disease associations

Potential involvement in inflammationPossible role in cancer or infection due to influence on NF-κB signaling[1][2]
05

Safety considerations

None specifically reported for TIFAB as a drug target; its role is modulatory and would present therapeutic challenges due to protein-protein interaction and lack of druggability.
06

Interacting drugs

None known; TIFAB is not targeted by approved drugs and acts primarily as a protein-protein interaction modulator[3].
07

Biomarkers

None established; not a validated biomarker for patient selection or efficacy monitoring.

Beyond the preview

Go deeper on TRAF-interacting protein with FHA domain-containing protein B (TIFAB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRAF-interacting protein with FHA domain-containing protein B (TIFAB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call